Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency (AATD).
- AATD is an autosomal recessive disorder frequently caused by missense mutations in the A1AT gene.
- Individuals with AATD regularly suffer from chronic obstructive pulmonary disease and/or liver disease.
- In both PiMZ subjects dosed with 15 mg/kg BID of ZF874, the observed increase in functional A1AT was between 3.5 and 6 micromolar.
- Consistent with a pharmacological effect for ZF874, A1AT levels returned to baseline by 28 days after dosing.
- Pharmacokinetic analysis showed a two-fold higher exposure to ZF874 in one subject.
- CNTA shares are plunging as investors react when this one subject did show a two-fold increase in functional A1AT but also experienced severe liver toxicity, with a delayed, reversible increase in ALT and AST (enzymes suggesting liver damage).
- All other liver function tests remained in the normal range.
- Read Next: Centessa Stock Surges On Positive Data From Hemophilia Candidate.
- Price Action: CNTA shares are down 18.55% at $14.01 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!